Cargando…

Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety

BACKGROUND: Gastric cancer is the fifth cause of cancer incidence worldwide. Multidisciplinary approaches that improve the survival are needed. Perioperative chemotherapies show improvement in pathological complete remission (pCR) and overall survival (OS), but less than 50% of the patients complete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villanueva, Luis, Anabalon, Jaime, Butte, Jean M, Salman, Pamela, Panay, Sergio, Milla, Elizabeth, Gallardo, Carlos, Hoefler, Sebastian, Charles, Roberto, Reyes, Felipe, Barajas, Olga, Matamala, Luis, Molina, Angelica, Portiño, Sergio, Berrios, Marcela, Caglevic, Christian, Mahave, Mauricio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929772/ https://www.ncbi.nlm.nih.gov/pubmed/33680082 http://dx.doi.org/10.3332/ecancer.2021.1168

Ejemplares similares

Triple-negative breast cancer: the reality in Chile and in Latin America
por: Caglevic, Christian, et al.
Publicado: (2019)

Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma
por: Zeng, Hanqing, et al.
Publicado: (2022)

The Evolution of Neo-Adjuvant Therapy in the Treatment of Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas
por: Dermanis, Alexander A., et al.
Publicado: (2023)

Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction
por: Li, Minmin, et al.
Publicado: (2014)

KCNQ potassium channels modulate Wnt activity in gastro-oesophageal adenocarcinomas
por: Shorthouse, David, et al.
Publicado: (2023)

Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma()
por: Woolston, Caroline M., et al.
Publicado: (2013)

The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction
por: Curtis, Nathan J, et al.
Publicado: (2014)

Combined Therapy of Locally Advanced Oesophageal and Gastro–Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors
por: Vošmik, Milan, et al.
Publicado: (2021)

Evidence of response to pembrolizumab in a patient with Lynch syndrome-related metastatic colon cancer
por: Salman, Pamela, et al.
Publicado: (2018)

Significance of tumour regression in lymph node metastases of gastric and gastro‐oesophageal junction adenocarcinomas
por: Reim, Daniel, et al.
Publicado: (2020)

Minimally invasive surgery for gastro-oesophageal junction adenocarcinoma: Current evidence and future perspectives
por: Bîrlă, Rodica, et al.
Publicado: (2023)

A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma
por: Eatock, M M, et al.
Publicado: (2000)

Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas
por: Bain, G H, et al.
Publicado: (2014)

Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas
por: Bain, G H, et al.
Publicado: (2015)

Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas
por: Bain, G H, et al.
Publicado: (2016)

Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
por: Propper, David, et al.
Publicado: (2016)

Non-erosive gastro-oesophageal reflux disease and incidence of oesophageal adenocarcinoma in three Nordic countries: population based cohort study
por: Holmberg, Dag, et al.
Publicado: (2023)

Gastro-Œsophageal Intussusception
Publicado: (1935)

Role and new perspectives of transforming growth factor-α (TGF- α) in adenocarcinoma of the gastro-oesophageal junction
por: D'Errico, A, et al.
Publicado: (2000)

Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours
por: Thomaschewski, Michael, et al.
Publicado: (2018)

Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma
por: Cabeza-Segura, Manuel, et al.
Publicado: (2022)

Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma
por: GÜRLER, Fatih, et al.
Publicado: (2022)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO
por: Götze, Thorsten O., et al.
Publicado: (2021)

Effect of prehabilitation in gastro-oesophageal adenocarcinoma: study protocol of a multicentric, randomised, control trial—the PREHAB study
por: Le Roy, Bertrand, et al.
Publicado: (2016)

Safety and feasibility of preoperative exercise training during neoadjuvant treatment before surgery for adenocarcinoma of the gastro‐oesophageal junction
por: Christensen, J. F., et al.
Publicado: (2018)

Adenocarcinoma of oesophagus involving gastro-oesophageal junction following mini-gastric bypass/ one anastomosis gastric bypass
por: Aggarwal, Sandeep, et al.
Publicado: (2020)

The current situation for gastric cancer in Chile
por: Caglevic, Christian, et al.
Publicado: (2016)

Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival
por: Runkel, Mira, et al.
Publicado: (2021)

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
por: Wainberg, Z A, et al.
Publicado: (2011)

A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma
por: Starling, N, et al.
Publicado: (2009)

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
por: Feilchenfeldt, J, et al.
Publicado: (2015)

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
por: Feilchenfeldt, J, et al.
Publicado: (2015)

EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus
por: Birkman, Eva-Maria, et al.
Publicado: (2016)

Gastro-oesophageal reflux disease and eosinophilic oesophagitis: What is the relationship?
por: Wong, Stephanie, et al.
Publicado: (2018)

Sensory Phenotype of the Oesophageal Mucosa in Gastro-Oesophageal Reflux Disease
por: Ustaoglu, Ahsen, et al.
Publicado: (2023)

Tonsillar metastasis of oesophageal adenocarcinoma
por: Struijs, Bram, et al.
Publicado: (2007)

Completion of FLOT Therapy, Regardless of Tumor Regression, Significantly Improves Overall Survival in Patients with Esophageal Adenocarcinoma
por: Stüben, Björn-Ole, et al.
Publicado: (2022)

Hypoxia-inducible factor-1α expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas
por: Griffiths, E A, et al.
Publicado: (2007)

Spontaneous and inducible apoptosis in oesophageal adenocarcinoma
por: Raouf, A, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_gf6c62kh7rkk87lvnn2mm3odij